📊 GEHC Key Takeaways
Is GEHC a Good Investment? Thesis Analysis
GEHC demonstrates solid profitability with 40% gross margins and 20.1% ROE, supported by 4.8% revenue growth. However, negative free cash flow of -$138M despite $344M operating cash flow raises concerns about capital intensity and cash generation sustainability, requiring operational leverage improvements.
Why Buy GEHC? Key Strengths
- Strong profitability metrics with 40% gross margin and 13.4% operating margin indicating pricing power and operational efficiency
- Robust return on equity at 20.1% demonstrates effective capital deployment relative to shareholder investment
- Consistent revenue growth of 4.8% YoY in medical device sector shows market demand and competitive positioning
GEHC Investment Risks to Consider
- Negative free cash flow of -$138M signals capital expenditure significantly exceeds operating cash generation, raising sustainability concerns
- High leverage with 0.96x debt/equity ratio and $10B long-term debt represents material financial risk relative to $10.4B equity base
- Deteriorating cash conversion despite positive net income growth suggests operational cash generation is weakening relative to profitability
Key Metrics to Watch
- Free cash flow trend and operating cash flow sustainability to assess if capital intensity is improving
- Debt/equity ratio movement as company scales to ensure leverage remains manageable
- Operating margin expansion potential to drive cash conversion efficiency and offset capital expenditure requirements
GEHC Financial Metrics
💡 AI Analyst Insight
GE HealthCare Technologies Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
GEHC Profitability Ratios
GEHC vs Default Sector
How GE HealthCare Technologies Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GEHC Overvalued or Undervalued?
Based on fundamental analysis, GE HealthCare Technologies Inc. has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GEHC Balance Sheet & Liquidity
GEHC 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: GE HealthCare Technologies Inc.'s revenue has shown modest growth of 5% over the 5-year period. The most recent EPS of $3.03 reflects profitable operations.
GEHC Growth Metrics (YoY)
GEHC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.9B | $446.0M | $0.98 |
| Q2 2025 | $4.8B | $428.0M | $0.93 |
| Q1 2025 | $4.7B | $374.0M | $0.81 |
| Q3 2024 | $4.8B | $375.0M | $0.82 |
| Q2 2024 | $4.8B | $418.0M | $0.91 |
| Q1 2024 | $4.7B | $372.0M | $0.41 |
| Q3 2023 | $4.6B | $375.0M | $0.82 |
| Q2 2023 | $4.5B | $418.0M | $0.91 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GEHC Capital Allocation
GEHC SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for GE HealthCare Technologies Inc. (CIK: 0001932393)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GEHC
What is the AI rating for GEHC?
GE HealthCare Technologies Inc. (GEHC) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are GEHC's key strengths?
Claude: Strong profitability metrics with 40% gross margin and 13.4% operating margin indicating pricing power and operational efficiency. Robust return on equity at 20.1% demonstrates effective capital deployment relative to shareholder investment.
What are the risks of investing in GEHC?
Claude: Negative free cash flow of -$138M signals capital expenditure significantly exceeds operating cash generation, raising sustainability concerns. High leverage with 0.96x debt/equity ratio and $10B long-term debt represents material financial risk relative to $10.4B equity base.
What is GEHC's revenue and growth?
GE HealthCare Technologies Inc. reported revenue of $20.6B.
Does GEHC pay dividends?
GE HealthCare Technologies Inc. pays dividends, with $64.0M distributed to shareholders in the trailing twelve months.
Where can I find GEHC SEC filings?
Official SEC filings for GE HealthCare Technologies Inc. (CIK: 0001932393) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GEHC's EPS?
GE HealthCare Technologies Inc. has a diluted EPS of $4.55.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GEHC a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, GE HealthCare Technologies Inc. has a HOLD rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GEHC stock overvalued or undervalued?
Valuation metrics for GEHC: ROE of 20.1% (sector avg: 15%), net margin of 10.1% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy GEHC stock in 2026?
Our dual AI analysis gives GE HealthCare Technologies Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GEHC's free cash flow?
GE HealthCare Technologies Inc.'s operating cash flow is $344.0M, with capital expenditures of $482.0M. FCF margin is -0.7%.
How does GEHC compare to other Default stocks?
Vs Default sector averages: Net margin 10.1% (avg: 12%), ROE 20.1% (avg: 15%), current ratio 1.37 (avg: 1.8).